Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Kotobuki Pharmaceutical.

    Client Virtual Booth

    KOTOBUKI PHARMACEUTICAL

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Kotobuki Pharmaceutical
    japan Flag
    Country
    Country
    Japan
    Address
    Address
    Nagano
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://ssl.kotobuki-pharm.co.jp/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Astellas Launches XOSPATA (Gilteritinib) in Singapore to Treat Adult Leukaemia Patients

    Details:

    Xospata (gilteritinib) is a small molecule that inhibits multiple receptor tyrosine kinases, including FLT3. It is approved for the treatment of relapsed/refractory acute myeloid leukaemia with a FLT3 mutation.


    Lead Product(s): Gilteritinib Fumarate

    Therapeutic Area: Oncology Product Name: Xospata

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: Astellas Pharma

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable March 31, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Health Canada Approves Astellas' XOSPATA® (gilteritinib) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

    Details:

    Xospata (gilteritinib) is a small molecule that inhibits multiple receptor tyrosine kinases, including FLT3. It is approved for the treatment of relapsed/refractory acute myeloid leukaemia with a FLT3 mutation.


    Lead Product(s): Gilteritinib Fumarate

    Therapeutic Area: Oncology Product Name: Xospata

    Highest Development Status: ApprovedProduct Type: Small molecule

    Recipient: Astellas Pharma

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 14, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search